Interview: Roche to seize leap-frog opportunity in lung cancer

LONDON (Reuters) - After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer.

FILE PHOTO: World's biggest maker of cancer drugs Roche CEO Severin Schwan attends a news conference in Basel, Switzerland February 1, 2017. REUTERS/Ruben Sprich

“We have a real chance to be at the forefront here,” Chief Executive Severin Schwan said on Wednesday. “Our ambition is to become a clear leader in the field of cancer immunotherapies.”

At the same time he warned many investors would lose money across the industry as a large proportion of the hundreds of cancer trials now underway failed, leaving just a few winners.

His optimism for Roche has been buoyed by study results showing its immune-boosting medicine Tecentriq given with chemotherapy and the older drug Avastin significantly cut the risk of lung cancer worsening.

Researchers will detail the scale of that benefit, versus chemotherapy and Avastin alone, in a keenly awaited presentation at a medical meeting in Geneva on Thursday.

“We have the potential to get into the lead in first-line lung cancer,” Schwan said. “In all likelihood we have a medicine here that will potentially change the standard of care ... but we will also have to see how it compares with other therapies.”

Overall survival (OS) data will also be crucial in determining the ultimate winner in lung cancer - by far the biggest oncology market - since one of the main benefits of using immunotherapy is its long-lasting effects.

Roche does not yet have that OS data but initial observations are “encouraging” and it expects results in the first half of 2018, well ahead of OS findings with a competing drug combination including chemotherapy from Merck & Co.

Schwan needs Tecentriq to be a success to help replace revenue from older biological cancer drugs whose patents have expired or will shortly, exposing them to cheaper so-called biosimilar competition.

“On the pipeline side, we’re even more de-risked than a year ago ... but there is no doubt that the impact from biosimilars will be significant,” Schwan told Reuters.

“On balance, I‘m now very confident that we should be able to compensate for this erosion.”

Reporting by Ben Hirschler; editing by Alexander Smith

Our Standards:The Thomson Reuters Trust Principles.